NZ505951A - A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening - Google Patents

A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening

Info

Publication number
NZ505951A
NZ505951A NZ505951A NZ50595199A NZ505951A NZ 505951 A NZ505951 A NZ 505951A NZ 505951 A NZ505951 A NZ 505951A NZ 50595199 A NZ50595199 A NZ 50595199A NZ 505951 A NZ505951 A NZ 505951A
Authority
NZ
New Zealand
Prior art keywords
drug
cyclodextrin
enhancing
opening
heterocycloc
Prior art date
Application number
NZ505951A
Inventor
Thorsteinn Loftsson
Mar Masson
Einar Stefansson
Original Assignee
Cyclops Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclops Ehf filed Critical Cyclops Ehf
Publication of NZ505951A publication Critical patent/NZ505951A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for enhancing the complexation efficiency of a benzodiazepine with cyclodextrin comprising: complexing benzodiazepine with cyclodextrin in an aqueous medium at a pH level below 5 and allowing the resultant complexation medium to equilibrate for sufficient time to effect chemically reversible ring-opening of at least 1% by weight of benzodiazepine, an d further comprising detecting the presence of the ring-opened form of benzodiazepine.
NZ505951A 1998-02-23 1999-02-16 A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening NZ505951A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7554498P 1998-02-23 1998-02-23
PCT/IS1999/000003 WO1999042111A1 (en) 1998-02-23 1999-02-16 High-energy cyclodextrin complexes

Publications (1)

Publication Number Publication Date
NZ505951A true NZ505951A (en) 2003-02-28

Family

ID=22126450

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ505951A NZ505951A (en) 1998-02-23 1999-02-16 A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening

Country Status (7)

Country Link
EP (1) EP1067942A1 (en)
JP (1) JP2003522207A (en)
AU (1) AU759280C (en)
CA (1) CA2320772A1 (en)
IS (1) IS5572A (en)
NZ (1) NZ505951A (en)
WO (1) WO1999042111A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030391A2 (en) * 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
AU4866001A (en) * 2000-03-28 2001-10-08 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
NZ530227A (en) 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
WO2003022270A1 (en) * 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Transdermal administration of an enalapril ester
BR0311722A (en) * 2002-06-13 2005-03-01 Novartis Ag Quaternized ammonia cyclodextrin compounds
BR122018068797B1 (en) 2003-03-28 2021-04-27 Ares Trading S.A. PHARMACEUTICAL COMPOSITIONS OF COMPLEX CYCLODEXTRIN-CLADRIBINE COMPLEX, USES OF THE COMPLEX, AS WELL AS PROCESSES FOR ITS PREPARATION
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1729724A4 (en) 2003-12-31 2008-07-23 Cydex Inc Inhalent formulation containing sulfoalkyl ether gamma-cyclodextryn and corticosteroid
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CA2562585A1 (en) 2004-04-23 2005-11-10 Cydex, Inc. Dpi formulation containing sulfoalkyl ether cyclodextrin
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
ES2542893T3 (en) 2005-10-26 2015-08-12 Cydex Pharmaceuticals, Inc. Sulfoalkyl cyclodextrin compositions and methods of preparation thereof
EA200900571A1 (en) * 2006-10-20 2009-12-30 Айкос Корпорейшн COMPOSITIONS CHK1 INHIBITORS
BRPI0719096A2 (en) * 2006-11-21 2013-12-03 Novartis Ag STABLE PARENTAL FORMULATION CONTAINING AN RSV INHIBITOR OF A BENZODIAZEPINA STRUCTURE
CN104800210B (en) 2007-04-27 2019-08-06 锡德克斯药物公司 Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method
EP2106786A1 (en) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmaceutical preparation comprising permethylated cyclodextrin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US20110318474A1 (en) 2008-12-29 2011-12-29 Mark John Berry Food products enriched with methylxanthines
KR101743591B1 (en) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
AU2011254726B2 (en) 2010-05-19 2014-03-06 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol
CA2827336C (en) 2011-02-23 2016-01-26 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
EP2814849B8 (en) 2012-02-15 2020-03-04 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
RU2747757C2 (en) 2012-02-28 2021-05-13 Сидекс Фармасьютикалс, Инк. Compositions of alkylated cyclodextrin and methods of their preparation and application
UA121095C2 (en) 2012-10-22 2020-04-10 Сідекс Фармасьютікалс, Інк. Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014075935A1 (en) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CN104918622A (en) 2012-12-11 2015-09-16 赛博尔泰克股份公司 Delphinidin for combating melanoma cells
FI3183295T3 (en) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation

Also Published As

Publication number Publication date
WO1999042111A1 (en) 1999-08-26
AU759280B2 (en) 2003-04-10
IS5572A (en) 2000-08-16
CA2320772A1 (en) 1999-08-26
AU2638599A (en) 1999-09-06
JP2003522207A (en) 2003-07-22
EP1067942A1 (en) 2001-01-17
AU759280C (en) 2004-01-22

Similar Documents

Publication Publication Date Title
NZ505951A (en) A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
EP1176920A4 (en) Method for injecting a contrast medium to generate prolonged uniform vascular enhancement
ATE229012T1 (en) NEW TAXAND DERIVATIVES
HK1045022A1 (en) Memory, wrinting apparatus, reading apparatus, writing method, and reading method.
GT200000137A (en) PYRIMIDINE - 2, 4, 6 - METALOPROTEINASE INHIBITING TRIONES.
GB2345077A (en) Methods for deposition of materials in underground reservoirs
AP2003002790A0 (en) Furan polymer impregenated wood method for preparing the polymer and uses thereof
IT1307234B1 (en) FERMENTATION TANK, PARTICULARLY FOR THE RED VINIFICATION.
AU3569501A (en) Method for preparing functionalised polyalkylenimines, composition containing same and uses thereof
AU5227200A (en) Method for separating in an aqueous medium lanthanides and/or actinides by combined complexing-nanofiltration, and novel complexing agents therefor
MXPA01010955A (en) Method for producing aqueous alkaline solutions or reduced indigoid dyes.
HUP0300495A3 (en) Optically active structure for personalizing cards and the like, and method for the production thereof
GR3018213T3 (en) Composition comprising a succinoglycane.
EP1103553A3 (en) Substituted heterocyclic derivatives
EP1106619A3 (en) Threading intercalator having oxidation-reduction activity
BG106517A (en) Ciclesonide-containing aqueous pharmaceutical composition
AR245591A1 (en) Oral rinse compositions
MY123537A (en) Method of stabilizing n-oxyl compounds in vinyl compounds
AU2383697A (en) Use of aspartic acid-containing polymers in cooling circuits with added biocides
HUP0301095A3 (en) Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
MXPA01009604A (en) Cocoa powder for use in multi-layered gel-based dessert products and method for making same.
WO2001042250A3 (en) Process for production of diphenyl-dialkoxysilane, phenylalkyl-dialkoxysilane, octaphenylcyclotetrasiloxane and sym-tetraalkyltetraphenyl-cyclotetrasiloxane
ZA200204492B (en) Heterocyclic derivatives.
MXPA03003400A (en) Aerobic fermentation method.
EP0923932A4 (en) Composition containing antitumor agent

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF DISCLAIMER

PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended